 I. To evaluate the 4-month progression-free survival rate, response rate and toxicity of BAY 43-9006 in patients with progressing regional or metastatic transitional cell carcinoma or mixed histologies containing a component of TCC of the urothelium who have progressed on one and only one prior systemic chemotherapy regimen for metastatic disease. 